Search Results
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
content:https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-promising-interim-phase-iii-results-from-the-ongoing-first-in-human-study-evaluating-its-cd44v9-directed-antibody-drug-conjugate-amt-116-in-heavily-pretreated-egfr-wild-type-non-small-cell-lung--302587390.html
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 09:30 ET Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
domestic business expansion and the implementation of service standardization for the Joint Venture Platform. III. Strategic Value and Shareholder Returns: The Long-term Logic of Capital-Industry Resonance Regarding this
More news about: Visionary Holdings Inc.
Oct 17, 2025, 08:45 ET October 28, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against DOW
pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S
More news about: Levi & Korsinsky, LLP
Oct 17, 2025, 08:45 ET Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv)
More news about: Levi & Korsinsky, LLP
Oct 17, 2025, 08:45 ET Levi & Korsinsky Notifies Fluor Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - FLR
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: Levi & Korsinsky, LLP
Oct 17, 2025, 08:45 ET Investors in Nutex Health Inc. Should Contact Levi & Korsinsky Before October 21, 2025 to Discuss Your Rights - NUTX
that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal
More news about: Levi & Korsinsky, LLP
Oct 17, 2025, 07:17 ET Natural Grocers® Invites Customers to a "Spooktacular" Family-Friendly Halloween Event, Oct. 25, 2025
valid Nov. 20 – 26. [ iii] FOLLOW, DOWNLOAD & SUBSCRIBEStay connected
More news about: Natural Grocers by Vitamin Cottage, Inc.
Oct 17, 2025, 07:00 ET Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Pain: 3- and 6-Month Results from the COMFORT 2 Study. Chronic Pain & Management. 2025; 9: 171. DOI: 10.29011/2576-957X.1000171 iii Hatheway, J. A., Ratino, T., Swain, A. R., Ratino, T., Latif, U., Arulkumar, S., & Desai, M. J. (2025). Long-term pain relief delivered by micro-implantable
More news about: Boston Scientific Corporation
Oct 17, 2025, 06:05 ET MOH INVESTOR DEADLINE: Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Healthcare's "medical cost trend assumptions"; (ii) that Molina Healthcare was experiencing a "dislocation between premium rates and medical cost trend"; (iii) that Molina Healthcare's near term growth was dependent on a lack of "utilization of behavioral health, pharmacy, and inpatient and outpatient services";
More news about: Robbins Geller Rudman & Dowd LLP
Oct 17, 2025, 05:42 ET Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
The approval is based on a multi-center, randomized, open-label, controlled, Phase 3 KL166-III-06 study that evaluates the efficacy and safety profile of trastuzumab botidotin versus T-DM1 in patients with HER2-positive unresectable or metastatic
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 17, 2025, 02:00 ET Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)
announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan regarding development plans for two Phase III clinical trials of sparsentan in Japan (development code: RE-021) — one investigating the use of sparsentan in focal segmental glomerulosclerosis (FSGS)
More news about: Renalys Pharma, Inc.
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
the world's most stringent pharmaceutical regulatory market," said Wang Qunbin. It is worth noting that on 9 October, the Phase III clinical trial of HANSIZHUANG for perioperative gastric cancer met its primary endpoint, supporting an early drug application for market approval. This
More news about: Fosun
Oct 16, 2025, 22:06 ET Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed
More news about: Illumina
Oct 16, 2025, 19:24 ET NORDIC GROUP B.V. COMPARTE DATOS DEL GEL CANALICULAR LACRIFILL®
demostraciones de inyecciones. También podrán realizar pedidos en el stand. El nuevo informe del Taller sobre Ojo Seco TFOS (DEWS) III de la Sociedad de la Película Lagrimal y la Superficie Ocular (TFOS), publicado en el American Journal of Ophthalmology, citó dos estudios sobre
More news about: Nordic Pharma
Oct 16, 2025, 16:43 ET DIE NORDIC GROUP B.V. WIRD ÜBER IHRE TOCHTERGESELLSCHAFT NORDIC PHARMA, INC. (USA) IM RAHMEN DER AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025 PATIENTENDATEN UND ERFAHRUNGSBERICHTE ZU LACRIFILL® CANALICULAR GEL, EINER NEUARTIGEN THERAPIE FÜR TROCKENE AUGEN, VERÖFFENTLICHEN
teilzunehmen. Die Teilnehmer werden auch die Möglichkeit haben, am Stand Bestellungen aufzugeben. Der neue TFOS Dry Eye Workshop (DEWS) III-Bericht der Tear Film & Ocular Surface Society (TFOS), der im American Journal of Ophthalmology veröffentlicht wurde, zitiert in Abschnitt
More news about: Nordic Pharma
Oct 16, 2025, 16:41 ET NORDIC GROUP B.V., PAR L'INTERMÉDIAIRE DE SA FILIALE NORDIC PHARMA, INC. (U.S.), PARTAGERA DES DONNÉES PATIENTS ET UNE ÉTUDE SUR L'EXPÉRIENCE DES PATIENTS AVEC LE GEL CANALICULAIRE LACRIFILL®, UN NOUVEAU TRAITEMENT POUR LA SÉCHERESSE OCULAIRE, PENDANT LA CONFÉRENCE 2025 DE L'ACADÉMIE AMÉRICAINE D'OPHTHALMOLOGIE (AAO)
participants auront également la possibilité de passer des commandes sur le stand. Le nouveau rapport TFOS Dry Eye Workshop (DEWS) III de la Tear Film & Ocular Surface Society (TFOS), publié dans l'American Journal of Ophthalmology, cite deux études sur le nouveau produit
More news about: Nordic Pharma
Oct 16, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
demonstration sessions. Attendees will also have the opportunity to place orders at booth. The new TFOS Dry Eye Workshop (DEWS) III report from the Tear Film & Ocular Surface Society (TFOS), appeared in the American Journal of Ophthalmology, cited two studies of Nordic
More news about: Nordic Pharma
Oct 16, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
demonstration sessions. Attendees will also have the opportunity to place orders at booth. The new TFOS Dry Eye Workshop (DEWS) III report from the Tear Film & Ocular Surface Society (TFOS), appeared in the American Journal of Ophthalmology, cited two studies of Nordic
More news about: Nordic Pharma
Oct 16, 2025, 09:04 ET Clarity signs copper-67 Supply Agreement with Nusano
Clarity Pharmaceuticals, commented: "We are excited to continue growing our supply network for copper-67 in preparation for a registrational Phase III clinical trial with 67Cu-SAR-bisPSMA, our lead product aimed at improving the treatment paradigm for men suffering with prostate cancer. With
More news about: Clarity Pharmaceuticals
Oct 16, 2025, 09:00 ET Investors who lost money on Dow Inc.(DOW) should contact The Gross Law Firm about pending Class Action - DOW
pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times. DEADLINE:
More news about: Gross Law Firm
Oct 16, 2025, 09:00 ET SVRA LAWSUIT ALERT: The Gross Law Firm Notifies Savara Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv)
More news about: Gross Law Firm
Oct 16, 2025, 09:00 ET Contact The Gross Law Firm by November 14, 2025 Deadline to Join Class Action Against Fluor Corporation(FLR)
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: Gross Law Firm
Oct 16, 2025, 09:00 ET The Gross Law Firm Notifies Shareholders of Nutex Health Inc.(NUTX) of a Class Action Lawsuit and an Upcoming Deadline
that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal
More news about: Gross Law Firm
Oct 16, 2025, 08:47 ET Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
diftitox-cxdl) LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria
More news about: Citius Oncology, Inc.
Oct 16, 2025, 08:35 ET Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025
events related to the transplanted cells. Significant improvement in motor function: The MDS-UPDRS-III score improved by 21 points during the "OFF-period" and 9 points during the "ON-period", representing an improvement ratio exceeding 45%
More news about: UniXell Biotechnology